Contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. They are ideal for sensitive eyes and provide intensive, durable lubrication.
Contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. They are ideal for sensitive eyes and intensive dry eye symptoms.
Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. Vistitan™ is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for this indication in Canada and demonstrates that best ratio of safety to efficacy for this strength of the molecule. Aequus began Canadian promotional activities on behalf of its partner, for Vistitan™ in May 2016.
Aequus began promotional activities on Tacrolimus IR in December 2015. It was and remains the only lower cost alternative to the brand Prograf® currently marketed in Canada. Tacrolimus IR is indicated for the treatment and prevention of acute rejection following solid organ transplantation (liver, kidney and heart). Tacrolimus is part of a patient's immunosuppressive therapy prescribed chronically in their lifelong management to prevent graft rejection.
A once-daily topiramate product designed to improve patient compliance and to show an equivalent pharmacokinetic profile than the currently available immediate release products, which is dosed twice-daily. Aequus in-licensed Canadian commercial rights to Topiramate XR from Supernus Pharmaceuticals and is currently preparing an application to Health Canada seeking approval. Topiramate immediate release is currently approved in Canada for use in epilepsy and prophylactic migraine.
Pyridoxine/doxylamine is currently marketed as Diclegis® (United States)/Diclectin® (Canada) for the treatment of Nausea and Vomiting of Pregnancy. It is taken orally, dosed up to four times per day. A long-acting transdermal form of pyridoxine/doxylamine is being developed by Aequus to address the risk of missed doses due to emesis (vomiting), provide consistent symptomatic relief, ease pill burden, and improve compliance. Aequus is preparing for its first Proof of Concept study for this product, and intends to pursue a 505(b)2 pathway for regulatory approval in the United States.
Medical cannabis is lacking in three main categories - dose delivery, dose consistency, and clinical data support. Aequus' cannabinoid program is being developed to directly address these barriers. Throughout development Aequus will be working closely with patients and physicians with the goal to provide a cannabinoid product that is safe, consistent, targeted, and effective.
Has been involved in the Life Sciences industry for the past 19 years.
Currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies.
President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck.
Investment banker with Cormark Securities, acting as Managing Director of Life Sciences.
Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards.
Past winner of Business in Vancouver’s Top 40 Under 40 Award.
Background of operational and leadership experience in ophthalmology, with two of the largest ophthalmology companies in Canada and globally.
Worked with Allergan Canada for over 23 years, in a variety of roles across sales, marketing and management. Hi Last role at Allergan was Vice President, Regional President and General Manager, Canada.
Lead role as President and General Manager at Alcon Canada, the country’s leading ophthalmic med-device organization.
Principal at Fehr & Associates.
Served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX.
Has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution.
Treasurer and a Director for the Boys and Girls Clubs of South Coast BC since 2013.
Joined the Aequus team in August of 2020 in the role of Chief Commercial Officer.
Close to 20 years of senior management positions in North American eye care industry.
In-depth knowledge of Canadian Optometry, direct to consumer marketing, online technology, and medical devices, brings important experience to accelerate growth for Aequus’ expanding portfolio of products.
Past CEO of Eye Recommend, one of Canada’s largest cooperatives of optometrists.
Held senior leadership positions at Allergan, Nikon Optical Canada, and Digital ECP.
Over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry.
Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies.
Part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development.
Served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D.
5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.
Over 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector.
Financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems.
Chief Financial Officer at Neovasc Inc. and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company.
Received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998.
Honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.
20 yearsof experience in healthcare management and communications.
Joined Knight Therapeutics Inc. in 2014 in the roll of Vice President Commercial Operations following the successful sale of his company, Orphan Canada, to Knight.
Founder and Chief Commercial Officer of Orphan Canada (formerly GARD Therapeutics), Mr. Flowerday funded and led the company through in-licensing and commercializing of its lead products which dealt with genetic and rare diseases.
Established RxMedia Healthcare Communications, leading the company through a period of sustained growth and expansion.
Holds a Bachelor of Science (Honours) from the University of Toronto and a Masters of Business Administration from Queen’s University.
Associate Professor of Pharmacy Practice at the Arnold & Marie Schwartz College of Pharmacy since 2002.
Adjunct Associate Professor at NYU Langone Medical Center since 2011.
Received both her Bachelor of Science in Pharmacy and traditional Doctor of Pharmacy degrees from the Arnold & Marie Schwartz College of Pharmacy & Health Sciences.
Completed an ASHP-accredited specialized pharmacy residency in primary care at the Bay Pines Veterans Medical Center in Tampa, Fl.
Board Certified Pharmacotherapy Specialist, a Diplomat and Fellow of the Accreditation Council for Clinical Lipidology, and a Board Certified Clinical Lipid Specialist.
Serves as one of the Board of Directors for the Northeastern Lipid Association and on the Accreditation Council for Clinical Lipidology 's Board of Governors.
Also serves as the Adverse Drug Reactions Section Editor for the Journal of Pharmacy Practice.
Has presented on a national level in addition to local seminars,and has been invited to serve as a consultant at the Aegerion and Amarin Lipid Pharmaceuticals Advisory Board meetings, among others.